20 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 20 of 20 clinical reviews.
Is metformin effective for cancer prevention? We review the clinical evidence, dosing protocols, and limitations of off-label metformin use for reducing cancer risk.
Metformin is FDA-approved for type 2 diabetes, but observational data suggest it may reduce cancer incidence. Here is what the trials show, what remains unproven, and how to monitor patients using metformin off-label for cancer risk reduction.
A physician-reviewed analysis of metformin's off-label use for cancer prevention, including trial data, proposed mechanisms, risk-benefit tradeoffs, and who might benefit most.
A clinical evidence summary of metformin's off-label use for cancer prevention, including key trials, biological mechanisms, and current guideline positions.
Is metformin a longevity drug? We review the biology, clinical trial data from TAME and beyond, GRADE evidence levels, off-label status, and what prescribers and patients need to know before considering metformin for aging.
Evidence-based monitoring guide for off-label metformin use in longevity. Covers B12 testing, renal function, lactic acidosis risk, and the clinical trials shaping anti-aging metformin protocols.
Metformin is prescribed off-label for longevity based on observational data and preclinical evidence. Here is what the clinical trials show, how physicians dose it, and what TAME will tell us.
A clinical review of metformin's off-label use for longevity, including trial data, AMPK mechanisms, side effects, and who may or may not benefit from anti-aging metformin therapy.
A clinical deep-dive into whether metformin works for non-alcoholic fatty liver disease (NAFLD): current evidence grade, off-label dosing protocols, and what the guidelines actually say.
Metformin is sometimes prescribed off-label for nonalcoholic fatty liver disease (NAFLD). This evidence summary reviews the clinical trial data, guideline positions, and practical considerations for metformin use in NAFLD.
Metformin is widely prescribed off-label for NAFLD, but clinical trials show limited histological benefit. Learn the real evidence, risks, tradeoffs, and better-studied alternatives.
Metformin is sometimes used off-label for nonalcoholic fatty liver disease (NAFLD). Learn what the evidence shows, how monitoring works, and what guidelines recommend.
Metformin is widely prescribed off-label for polycystic ovary syndrome (PCOS). Learn the dosing protocol, clinical evidence from key trials, side effects, and how it compares to other PCOS treatments.
Metformin is widely prescribed off-label for polycystic ovary syndrome (PCOS). Review the clinical trial evidence, guideline recommendations, dosing protocols, and expected outcomes for metformin in PCOS management.
Metformin is widely prescribed off-label for polycystic ovary syndrome (PCOS). Learn the clinical evidence, recommended doses, monitoring protocols, and what to expect from treatment.
Metformin is used off-label for PCOS to improve insulin sensitivity, restore ovulation, and lower androgen levels. Learn what the clinical trials show, who benefits most, and what risks to weigh before starting.
A clinical evidence summary of off-label metformin use for weight maintenance, including trial data from the DPP/DPPOS, dosing guidance, and how it compares to newer GLP-1 therapies.
Metformin is FDA-approved for type 2 diabetes, but clinicians increasingly prescribe it off-label for weight maintenance. This evidence-based guide covers the clinical trial data, GRADE evidence levels, risks, and who may benefit most.
Metformin is used off-label for weight maintenance after initial weight loss. Review the clinical trial evidence, required lab monitoring, dosing protocols, and safety considerations for long-term use.
Metformin is FDA-approved for type 2 diabetes but is used off-label for weight maintenance. Learn what the clinical evidence shows, who may benefit, and how dosing is typically structured.